Related Experiment Videos
[Oxaliplatin: a first DACH-platinum in oncology]
118-20, rue Pasteur, 94278 Kremlin-Bicêtre Cedex.
Bulletin Du Cancer
|September 25, 2001
Summary
Oxaliplatin, a novel platinum salt, demonstrates significant antitumor activity and good clinical tolerance, especially in cisplatin-resistant cancers. Its combination therapies show promise for various solid tumors, expanding treatment options.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Background:
- Over 3,000 cisplatin analogues synthesized, but few in clinical development.
- Cisplatin and carboplatin were the main platinum-based drugs before oxaliplatin's approval.
- Oxaliplatin is the first approved diaminocyclohexane (DACH) platinum analogue.
Purpose of the Study:
- To evaluate the antitumoral activity and clinical tolerance of oxaliplatin.
- To investigate oxaliplatin's efficacy in cisplatin-resistant models.
- To explore combination therapies involving oxaliplatin.
Main Methods:
- In vitro and in vivo studies using cisplatin-resistant models and cell lines.
- Clinical trials assessing efficacy and toxicity.
- Combination studies with cytotoxic agents like 5FU, raltitrexed, irinotecan, and cisplatin.
Main Results:
- Oxaliplatin shows significant in vitro and in vivo antitumor activity, particularly in resistant models.
- Demonstrates good clinical tolerance with no renal or auditory toxicity and low hematotoxicity.
- Combination therapy, especially oxaliplatin with 5FU, is effective in metastatic colorectal cancer.
- Oxaliplatin exhibits activity in mismatch repair-deficient cells, resistant to other platinum drugs.
Conclusions:
- Oxaliplatin is a valuable new platinum-based chemotherapy agent.
- Its unique activity profile and tolerance suggest potential for broader applications in solid tumors.
- Combination therapies with oxaliplatin offer enhanced cytotoxic effects and expanded therapeutic indications.